文献速递眼底病与葡萄膜炎眼整形与眼眶

钌-106近距离放射治疗虹膜黑色素瘤与虹膜睫状体黑色素瘤

Ruthenium-106 brachytherapy for iris and iridociliary melanomas.
PubMed 文献 · Br J Ophthalmol · 2017-11-09

本研究评估钌-106(Ru106)近距离放射治疗作为虹膜黑色素瘤(IM)与虹膜睫状体黑色素瘤(ICM)保眼治疗的疗效,2006至2016年间共88例患者接受治疗。3年无局部失败生存率为98.9%(SE 1.2%),保眼率为97.7%,治疗相关毒性多为轻度,且未影响视力。

要点

  • 3年无局部失败生存率为98.9%(SE 1.2%),保眼率为97.7%。
  • 治疗相关毒性发生率为80.7%,多为轻度,常见者为白内障加重或新发(51.1%)、干眼(29.5%)和青光眼(20.5%)。
  • 随访时仅2.3%的患者视力低于0.33(低视力)。

核心结论

  • Ru106治疗IM与ICM可获得极佳的局部控制(98.9%)和保眼率(97.7%)。
  • 毒性常见,但多为轻度且为一过性。
  • Ru106未影响视力。
  • 随访期间无因黑色素瘤导致的死亡。

研究设计与样本

  • 2006年至2016年间,88例患者接受Ru106近距离放射治疗。
  • 主要结局为局部控制,次要结局为转移、生存、保眼、并发症和视力。
  • 88例中58例(65.9%)为IM,30例(34.1%)为ICM;ICM平均而言较IM更大、更晚期。

主要发现

  • 总体中位随访时间为36个月。
  • 3年无局部失败生存率为98.9%(SE 1.2%)。
  • 3年无转移生存率为98.2%(SE 1.8%);随访期间无因黑色素瘤导致的死亡。
  • 保眼率为97.7%。
  • 治疗相关毒性见于80.7%的患者,多为轻度;常见毒性为原有白内障加重或新发白内障(51.1%)、干眼(29.5%)和青光眼(20.5%)。

关键数值与推荐

  • 3年无局部失败生存率为98.9%(SE 1.2%)。
  • 3年无转移生存率为98.2%(SE 1.8%)。
  • 保眼率为97.7%。
  • 治疗相关毒性发生率为80.7%;白内障加重或新发为51.1%,干眼为29.5%,青光眼为20.5%。
  • 随访时视力低于0.33(低视力)者为2.3%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: To evaluate ruthenium-106 (Ru106) brachytherapy as eye-conserving treatment of iris melanomas (IMs) and iridociliary melanomas (ICMs). MATERIALS AND METHODS: Eighty-eight patients received Ru106 brachytherapy between 2006 and 2016. Primary outcome was local control, and secondary outcomes were metastasis, survival, eye preservation, complications and visual acuity (VA). RESULTS: Overall median follow-up was 36 months. Of 88 patients, 58 (65.9%) had IM and 30 (34.1%) had ICM. ICM were on average larger and more advanced than IM. Local failure-free survival at 3years was 98.9% (SE 1.2%). Metastasis-free survival was 98.2% (SE 1.8%) at 3years; no deaths due to melanoma occurred during follow-up. Eye preservation rate was 97.7%. Treatment-related toxicities were mostly mild and observed in 80.7% of the patients. Common toxicities were worsening of pre-existing or new cataract (51.1%), dry eyes (29.5%) and glaucoma (20.5%). VA was not affected by Ru106 brachytherapy, with only 2.3% having VA <0.33 (low vision) at follow-up. CONCLUSIONS: Ru106 for IM and ICM yielded excellent local control (98.9%) and eye preservation (97.7%). Toxicities were common, but mostly mild and transient. Moreover, Ru106 did not affect visual acuity.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Marinkovic M, Horeweg N, Laman MS, et al. Ruthenium-106 brachytherapy for iris and iridociliary melanomas. Br J Ophthalmol. 2017. PMID: 29122824. doi:10.1136/bjophthalmol-2017-310688

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。